Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults With Alcohol-related Liver Disease (ALD)

Next Previous
Trial Profile

A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults With Alcohol-related Liver Disease (ALD)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gatuzosiran (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STARLIGHT
  • Sponsors GSK

Most Recent Events

  • 01 Apr 2026 Planned End Date changed from 30 Mar 2028 to 7 Mar 2028.
  • 12 Feb 2026 Planned End Date changed from 23 Aug 2027 to 30 Mar 2028.
  • 12 Feb 2026 Planned primary completion date changed from 8 Dec 2026 to 2 Aug 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top